Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation

Seminars in Oncology

Volumn 39, Issue 6, 2012, Pages 683-693

  Luznik, Leo ^a,b   O'Donnell, Paul V ^c,d   Fuchs, Ephraim J ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; HLA ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 84870654815     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.09.005     Document Type: Article

References (67)

1. P.G. Beatty, R.A. Clift, E.M. Mickelson Marrow transplantation from related donors other than HLA-identical siblings N Engl J Med 313 1985 765 771
2. C.D. Buckner, R.B. Epstein, R.H. Rudolph, R.A. Clift, R. Storb, E.D. Thomas Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia Blood 35 1970 741 750
3. R.A. Clift, J.A. Hansen, E.D. Thomas Marrow transplantation from donors other than HLA-identical siblings Transplantation 28 1979 235 242
4. R.L. Powles, G.R. Morgenstern, H.E. Kay Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia Lancet 1 1983 612 615
5. T.R. Spitzer Engraftment syndrome following hematopoietic stem cell transplantation Bone Marrow Transplant 27 2001 893 898
6. R. Szydlo, J.M. Goldman, J.P. Klein Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings J Clin Oncol 15 1997 1767 1777
7. Y. Reisner, N. Kapoor, D. Kirkpatrick Transplantation for acute leukaemia with HLA-A and B nonidentical parental marrow cells fractionated with soybean agglutinin and sheep red blood cells Lancet 2 1981 327 331
8. R.C. Ash, M.M. Horowitz, R.P. Gale Bone marrow transplantation from related donors other than HLA-identical siblings: effect of T cell depletion Bone Marrow Transplant 7 1991 443 452
9. F. Aversa, A. Tabilio, A. Velardi Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype N Engl J Med 339 1998 1186 1193
10. F. Aversa, A. Terenzi, A. Tabilio Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse J Clin Oncol 23 2005 3447 3454
11. L. Ruggeri, M. Capanni, E. Urbani Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2002 2097 2100
12. J. Mehta, S. Singhal, A.P. Gee Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients Bone Marrow Transplant 33 2004 389 396
13. A.M. Leen, A. Christin, G.D. Myers Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation Blood 114 2009 4283 4292
14. P.J. Amrolia, G. Muccioli-Casadei, H. Huls Adoptive immunotherapy with allodepleted donor T-cells improves immune reconstitution after haploidentical stem cell transplantation Blood 108 2006 1797 1808
15. M. Di Ianni, F. Falzetti, A. Carotti Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation Blood 117 2011 3921 3928
16. K. Perruccio, F. Topini, A. Tosti Photodynamic purging of alloreactive T cells for adoptive immunotherapy after haploidentical stem cell transplantation Blood Cells Mol Dis 40 2008 76 83
17. E.C. Guinan, V.A. Boussiotis, D. Neuberg Transplantation of anergic histoincompatible bone marrow allografts N Engl J Med 340 1999 1704 1714
18. Y. Reisner, D. Hagin, M.F. Martelli Haploidentical hematopoietic transplantation: current status and future perspectives Blood 118 2011 6006 6017
19. L. Luznik, E.J. Fuchs High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation Immunol Res 47 2010 65 77
20. R. Schwartz, W. Dameshek Drug-induced immunological tolerance Nature 183 1959 1682 1683
21. M.C. Berenbaum, I.N. Brown Prolongation of homograft survival in mice with single doses of cyclophosphamide Nature 200 1963 84
22. M.C. Berenbaum, I.N. Brown Dose-response relationships for agents inhibiting the immune response Immunology 7 1964 65 71
23. A.C. Aisenberg, B. Wilkes Immunological tolerance induced by cyclophosphamide assayed by plaque spleen cell method Nature 213 1967 498 499
24. G. Nirmul, C. Severin, R.N. Taub Cyclophosphamide-induced immunologic tolerance to skin homografts Surg Forum 22 1971 287 288
25. G. Nirmul, C. Severin, R.N. Taub Mechanisms and kinetics of cyclophosphamide-induced specific tolerance to skin allografts in mice Transplant Proc 5 1973 675 678
26. R.D. Owen Immunogenetic consequences of vascular anastomoses between bovine twins Science 102 1945 400 401
27. R.E. Billingham, L. Brent, P.B. Medawar Actively acquired tolerance of foreign cells Nature 172 1953 603 606
28. Y. Sharabi, D.H. Sachs Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen J Exp Med 169 1989 493 502
29. H. Mayumi, M. Umesue, K. Nomoto Cyclophosphamide-induced immunological tolerance: an overview Immunobiology 195 1996 129 139
30. K. Nomoto, M. Eto, K. Yanaga, Y. Nishimura, T. Maeda Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A J Immunol 149 1992 2668 2674
31. A. Matsuura, M. Katsuno, Y. Suzuki Cyclophosphamide-induced tolerance in fully allogeneic heart transplantation in mice Cell Immunol 155 1994 501 507
32. T. Shin, H. Mayumi, K. Himeno, H. Sanui, K. Nomoto Drug-induced tolerance to allografts in mice I. Difference between tumor and skin grafts Transplantation 37 1984 580 584
33. H. Mayumi, R.A. Good Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide J Exp Med 169 1989 213 238
34. M. Eto, H. Mayumi, Y. Tomita Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice J Immunol 146 1991 1402 1409
35. C. Gibbons, M. Sykes Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism Immunol Rev 223 2008 334 360
36. G. Strauss, W. Osen, K.M. Debatin Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs Clin Exp Immunol 128 2002 255 266
37. H. Waldmann Tolerance: an overview and perspectives Nat Rev Nephrol 6 2010 569 576
38. X.C. Li, L.A. Turka An update on regulatory T cells in transplant tolerance and rejection Nat Rev Nephrol 6 2010 577 583
39. Y.Y. Kong, M. Eto, K. Omoto, M. Umesue, A. Hashimoto, K. Nomoto Regulatory T cells in maintenance and reversal of peripheral tolerance in vivo J Immunol 157 1996 5284 5289
40. Y. Tomita, H. Mayumi, M. Eto, K. Nomoto Importance of suppressor T cells in cyclophosphamide-induced tolerance to the non-H-2-encoded alloantigens Is mixed chimerism really required in maintaining a skin allograft tolerance? J Immunol 144 1990 463 473
41. + T cells in GVHD prevention with high-dose posttransplantation cyclophosphamide (Cy) Blood 116 2010 3749
42. + regulatory T cells is vital for infectious transplantation tolerance J Exp Med 208 2011 2043 2053
43. M. Eto, H. Mayumi, Y. Tomita, Y. Yoshikai, K. Nomoto Intrathymic clonal deletion of V beta 6+ T cells in cyclophosphamide-induced tolerance to H-2-compatible, Mls-disparate antigens J Exp Med 171 1990 97 113
44. L. Luznik, L.W. Engstrom, R. Iannone, E.J. Fuchs Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation Biol Blood Marrow Transplant 8 2002 131 138
45. Y.L. Colson, S.M. Wren, M.J. Schuchert A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers J Immunol 155 1995 4179 4188
46. Y.L. Colson, H. Li, S.S. Boggs, K.D. Patrene, P.C. Johnson, S.T. Ildstad Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach J Immunol 157 1996 2820 2829
47. L. Luznik, S. Jalla, L.W. Engstrom, R. Iannone, E.J. Fuchs Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide Blood 98 2001 3456 3464
48. P.A. McSweeney, D. Niederwieser, J.A. Shizuru Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390 3400
49. P.V. O'Donnell, L. Luznik, R.J. Jones Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide Biol Blood Marrow Transplant 8 2002 377 386
50. L. Luznik, P.V. O'Donnell, H.J. Symons HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transplant 14 2008 641 650
51. S. Giralt, B. Logan, D. Rizzo Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program Biol Blood Marrow Transplant 13 2007 844 852
52. C.G. Brunstein, E.J. Fuchs, S.L. Carter et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts Blood 118 2011 282 288
53. D. Grosso, M. Carabasi, J. Filicko-O'Hara A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing Blood 118 2011 4732 4739
54. C. Anasetti, D. Amos, P.G. Beatty Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma N Engl J Med 320 1989 197 204
55. S.O. Ciurea, P.F. Thall, X. Wang Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation Blood 118 2011 5957 5964
56. H. Symons, A.R. Chen, L. Luznik Myeloablative haploidentical bone marrow transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high risk hematologic malignancies who lack conventional donors is welll tolerated and produces excellent relapse-free survival: results of a prospective phase II trial Blood 118 2011 4151
57. B.A.C.A. Sizemore, A. Bashey, M. Sanacore Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial Blood 118 2011 889
58. P.V. O'Donnell, T.A. Gooley, L. Luznik, E.J. Fuchs Cyclophosphamide- induced tolerance following bone marrow transplantation from haploidentical donors HE Haematol Ed Esp 95 2010 266 271
59. L. Vago, S.K. Perna, M. Zanussi Loss of mismatched HLA in leukemia after stem-cell transplantation N Engl J Med 361 2009 478 488
60. I.B. Villalobos, Y. Takahashi, Y. Akatsuka Relapse of leukemia with loss of mismatched HLA resulting from uniparental disomy after haploidentical hematopoietic stem cell transplantation Blood 115 2010 3158 3161
61. K. Raj, M. Streetly, M. Kazmi Peripheral blood progenitor cell (PBPC) transplantation from haploidentical donors following reduced intensity conditioning (RIC) for high-risk hematologic malignancies Biol Blood Marrow Transplant 18 2012 S331
62. S.O. Ciurea, R.M. Saliba, U.D. Bayraktar Improved early outcomes with T-cell replete (TCR) compared with T-cell depleted (TCD) haploidentical stem cell transplantation (HaploSCT) Blood 118 2011 320
63. L. Luznik, J. Bolanos-Meade, M. Zahurak et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease Blood 115 2010 3224 3230
64. L.M. Burroughs, P.V. O'Donnell, B.M. Sandmaier Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma Biol Blood Marrow Transplant 14 2008 1279 1287
65. A. Bashey, X. Zhang, C.A. Sizemore T-cell replete haploidentical transplantation using post-transplant cyclophosphamide results in equivalent non-relapse mortality and disease-free survival compared to transplantation from HLA-identical sibling and matched unrelated donors: a stratified Cox model analysis of two hundred and sixty contemporaneous allogeneic transplants from a single center Blood 118 2011 833
66. Y.L. Kasamon, L. Luznik, M.S. Leffell Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome Biol Blood Marrow Transplant 16 2010 482 489
67. H.J. Symons, M.S. Leffell, N.D. Rossiter, M. Zahurak, R.J. Jones, E.J. Fuchs Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation Biol Blood Marrow Transplant 16 2010 533 542